Prometic Life Sciences LTD

Human Genome Sciences is a biopharmaceutical company based in Rockville, MD. The company focuses on developing novel therapies and treatments for various diseases and medical conditions. With a commitment to advancing healthcare through innovative research and development, Human Genome Sciences aims to improve patient outcomes and quality of life through its cutting-edge scientific discoveries and pharmaceutical products. Generated from their business information

GlycoMimetics develops novel small molecule therapeutics based upon the roles that carbohydrates play in biological processes. The company believes that carbohydrate mimics, or glycomimetic compounds, represent a new class of drugs. It has identified some compounds with potential therapeutic utility. One class has potential in the treatment of infectious diseases with a novel mechanism of action; the second is a class of anti-inflammatory compounds that have been shown to reduce key measures of inflammation. One of GMI s lead opportunities is to treat or prevent infections caused by Pseudomonas aeruginosa. Its objective in this program is to develop a drug that would be used in conjunction with antibiotics against chronic infections that have failed to respond to antibiotic treatment. The company also has compounds that inhibit selectin binding. Its initial focus in this program is to develop a product to treat acute exacerbations of asthma and chronic obstructive pulmonary disease. GlycoMimetics is headquartered in Gaithersburg, Md.

OncoC4 is a pioneering biotechnology company based in Rockville, MD, founded by esteemed immunologists Dr. Yang Liu and Dr. Pan Zheng. The firm is dedicated to advancing innovative cancer therapies, leveraging years of research and the expertise of a skilled leadership team focused on clinical development for patients facing challenging cancers. With a diverse pipeline that includes programs targeting PD-1, VEGF, CTLA-4, and Siglec pathways, OncoC4 is positioned to offer promising treatment options. The company is supported by a robust advisory board and a network of investors and partners committed to transforming the landscape of cancer care. Generated from the website